僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E （IgE） with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research.